Mrd

Edit

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients ...

The Galveston Daily News 11 Dec 2025

AUSTIN, Texas--(BUSINESS WIRE)--Dec 10, 2025-- ....

Edit

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio ...

Nasdaq Globe Newswire 09 Dec 2025

Myriad Genetics will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) ... .

Edit

SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS

Business Wire 09 Dec 2025

MORRISVILLE, N.C.--(BUSINESS WIRE)-- #BreastCancer--SAGA Diagnostics to present data from two trials using Pathlight to evaluate neoadjuvant therapy outcomes in triple-negative breast cancer at SABCS ... .

Edit

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast

Hastings Tribune 09 Dec 2025

SALT LAKE CITY, Dec.

Edit

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile (Form 8-K) (Senti Biosciences Inc)

Public Technologies 09 Dec 2025

) Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile.

Edit

In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% (Form 8-K) (Immix Biopharma Inc)

Public Technologies 08 Dec 2025

- In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% - ... In four out of five pending patients, MRD ...

Edit

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ� Data Driving Treatment Interventions at ...

Nasdaq Globe Newswire 06 Dec 2025

Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH ... .

Edit

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ®

Caledonian Record 06 Dec 2025

SEATTLE, Dec.

Edit

Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting

PR Newswire 03 Dec 2025

This year's presentations reflect the growing integration of highly sensitive, circulating tumor DNA (ctDNA)-based MRD testing into clinical studies across hematologic malignancies ... Final results and phased-seq MRD analysis .

Edit

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene (Form 8-K) (BioNexus Gene Lab Corp)

Public Technologies 02 Dec 2025

BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene ... Strong Market Tailwinds in Liquid Biopsy and MRD.

Edit

SAGA Diagnostics Showcases New Pathlight™ MRD Data at SABCS 2025

The Galveston Daily News 01 Dec 2025

MORRISVILLE, N.C.--(BUSINESS WIRE)--Dec 1, 2025-- ....

Edit

Minimal Residual Disease (MRD) Testing Research Report 2025: Market to Reach $2.39 Billion by 2030, ...

Nasdaq Globe Newswire 01 Dec 2025

The Global MRD ... A trend is the adoption of MRD testing for solid tumors, with firms like Illumina investing in new assays.

Edit

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ� MRD Testing Across a Range of Blood ...

Nasdaq Globe Newswire 24 Nov 2025

Adaptive's clonoSEQ MRD Testing in Clinic and Research Settings Across ~90 Abstracts ... .

Edit

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a

The Eagle-Tribune 24 Nov 2025

SEATTLE, Nov.

Edit

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel

The Scientist 13 Nov 2025

Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs .

Podcasts:

Latest News for: mrd

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients ...

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio ...

SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile (Form 8-K) (Senti Biosciences Inc)

In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% (Form 8-K) (Immix Biopharma Inc)

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ� Data Driving Treatment Interventions at ...

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ®

Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene (Form 8-K) (BioNexus Gene Lab Corp)

SAGA Diagnostics Showcases New Pathlight™ MRD Data at SABCS 2025

Minimal Residual Disease (MRD) Testing Research Report 2025: Market to Reach $2.39 Billion by 2030, ...

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ� MRD Testing Across a Range of Blood ...

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel

Article Search

EXPLORE WN.com